Drug Profile

Hydrocodone/chlorphenamine extended-release - Covidien

Alternative Names: Chlorphenamine/hydrocodone; Chlorpheniramine/hydrocodone; Hydrocodone/chlorpheniramine; TussiCaps

Latest Information Update: 17 Nov 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mallinckrodt Inc.
Developer Covidien
Class Antiallergics; Antitussives; Indazoles; Indoles; Morphinans; Opioid analgesics; Sedating antihistamines
Mechanism of Action Histamine H1 receptor antagonists; Opioid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

17 Apr 2014 Hi-Tech Pharmacal has been acquired by Akorn
26 Aug 2011 Hydrocodone/chlorphenamine extended-release licensed to Hi-Tech Pharmacal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com